Program
atumelnant
Also written as “Atumelnant”, “atumelnant (CRN04894)” and “CRN04894 Oral Solution”.
Its studies are mostly in Adrenal Hyperplasia, Congenital · Cushing Syndrome, led by Vertex Pharmaceuticals.
Furthest: phase 3, since Aug 20, 20258 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 83 open or running | phase 3since Aug 20, 2025 | Mar 27, 2023 | May 2027phase 3 · NCT07144163 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 27, 2023First study: phase 2 study in Cushing SyndromeFirst studyNCT05804669 · 19 enrolled · United States
- Jun 8, 2023Phase 2 study in Adrenal Hyperplasia, CongenitalNCT05907291 · 38 enrolled · United States, Argentina, Brazil and more
- Sep 11, 2023Phase 1 study in Healthy VolunteersNCT06048887 · 88 enrolled · United States
- Nov 27, 2024Phase 2 study in Adrenal Hyperplasia, CongenitalNCT06712823 · 200 planned · United States, Argentina, Brazil and more
- Aug 20, 20252 phase 3 studies in Adrenal Hyperplasia, CongenitalNCT07144163, NCT07159841
- Oct 22, 2025Phase 1 study in Healthy VolunteersNCT07221084 · 21 enrolled · United States
- Apr 29, 2026Phase 1 study in Healthy VolunteersNCT07570082 · 46 enrolled · United States
Ahead
- May 2027Primary completion: phase 3 study in Adrenal Hyperplasia, CongenitalNCT07144163
- Jul 2029Primary completion: phase 2 study in Adrenal Hyperplasia, CongenitalNCT06712823
- Mar 2030Primary completion: phase 3 study in Adrenal Hyperplasia, CongenitalNCT07159841
TargetBeta
“An orally bioavailable nonpeptide antagonist of the adrenocorticotropic hormone (ACTH) receptor (ACTHR; melanocortin receptor 2; MC2R), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| OMS1620rule | omass-therapeutics-australia-proprietary-ltd | phase 1 | 1 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07570082Healthy Volunteers · United States | 1 | Completed | Jun 30, 2026 | 46 |
| NCT07221084Healthy Volunteers · United States | 1 | Completed | Feb 7, 2026 | 21 |
| NCT07159841Adrenal Hyperplasia, Congenital · United States, Argentina, Australia and more | 3 | Recruiting | Mar 2030 | 153 |
| NCT07144163Adrenal Hyperplasia, Congenital · United States, Argentina, Australia and more | 3 | Recruiting | May 2027 | 150 |
| NCT06712823Adrenal Hyperplasia, Congenital · United States, Argentina, Brazil and more | 2 | Recruiting | Jul 2029 | 200 |
| NCT06048887Healthy Volunteers · United States | 1 | Completed | Apr 11, 2022 | 88 |
| NCT05907291Adrenal Hyperplasia, Congenital · United States, Argentina, Brazil and more | 2 | Completed | Aug 22, 2025 | 38 |
| NCT05804669Cushing Syndrome · United States | 2 | Completed | Aug 25, 2026 | 19 |
How it is read
Names in the registry
- “Atumelnant”, 4 entries
- “atumelnant (CRN04894)”, 2 entries
- “atumelnant”, 1 entry
- “CRN04894 Oral Solution”, 1 entry
Conditions, from the studies’ own filings
- Adrenal Hyperplasia, Congenital, 4 studies
- Cushing Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.